AGENDA AT A GLANCE
8:50
IMAPAC’s Opening Address
Leadership Panel:
Indian Biologics Market: Trends & Future
9:00
Leadership Panel: India for the World: Biologics Potential and Global Strategy
- India’s competitive edge in biosimilars and large-scale manufacturing
- Strategic collaborations with global pharma for co-development
- Fostering a value-based ecosystem through affordable therapies, patient access, and clinical outcomes
- Future trajectory in the next 5 years
Moderator:
Panelists:
9:50
Reserved for M.R. Sanghavi & Co.
Keynote Address:
India’s Strengths for Affordable Therapies
10:15
India’s Strategic Advantage in Delivering Affordable Biologics and Advanced Therapies (TBC)
- Leveraging India's cost-effective R&D and manufacturing ecosystem
- Public-private partnerships driving access and innovation in biologics
- India's global role in supplying affordable therapies to emerging and developed markets
10:40
Morning Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking
Advancing from Research & Formulation to Clinical Trials
11:35
Pfanstiehl’s Arg-Glu* as Ideal Excipient for High Concentration Monoclonal Antibody Formulations
- Subcutaneous injections save patients‘ time and hospitalization costs
- Need for higher dose of monoclonal antibodies (mAb) formulations.
- Challenges of high dose mAb formulations
- Traditional high dose monoclonal antibody formulations (approved)
- Arg-Glu a promising candidate to address concerns of aggregation, viscosity, liquid-liquid phase separation and long term storage.
- Mechanism driving mAb stability in formulations containing Arg-Glu
12:00
A Simple and Easy Method to Detect Amyloid Formation in Therapeutical Protein and Peptides
- Amyloid risks in protein and peptide therapeutics
- Limitations of current amyloid detection methods
- Microfluidic, low-volume PoC detection approach to address current challenges.
- Discussion on Fluorescent and electrochemical validation strategies
12:50
Lunch Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking
Advances in Upstream & Downstream Processing
2:00
Harnessing Exosomes for Drug Delivery and Cell Therapy: Bridging Discovery, Development, and Deployment
- Exosomes stability, targeting ability, and biocompatibility make them ideal for drug delivery.
- How exosomes enhance drug delivery for small molecules, RNA, and gene-editing tools.
- The role of exosomes as cell-free alternatives to stem, dendritic, and NK cell therapies.
- Translational progress toward scalable, GMP-ready exosome platforms for clinical use.
2:40
Zumutor’s INABLR® Platform – a Comprehensive Human Monoclonal Antibody Library for Therapeutic Product Development.
- Overview of INABLR®, an integrated antibody discovery and engineering platform enabling rapid identification of high-affinity, developable fully human mAbs for therapeutic products.
- Screening strategies to identify potential hits from very large and diverse human antibody gene libraries using a combination of high throughput phage and yeast screening, in silico approaches and early developability assessments to de-risk candidates in discovery.
- Clinical validation through ZM008, a first-in-class NK cell immune checkpoint antibody in Phase 1 trials.
3:05
Afternoon Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking
Essential Vaccines for Future Resilience
Long-term Health Security & Supportive Policies
Happening in Regency Ballroom I
4:00
Novel Recombinant Vaccines to Combat Respiratory Infections
- At Mynvax, we work on development of novel recombinant protein sub-unit vaccines to combat respiratory infections.
- Our leading programs are in Influenza and RSV areas.
- We employ protein engineering-based techniques to develop novel candidates.
4:25
Reaching Zero Dose Children – Learnings from the Field
- Immunization Agenda 2030 (IA2030): A global strategy with the goal of reducing the number of zero-dose children by 50% by 2030 from the 2019 baseline.
- Gavi: Zero-Dose Immunization Program (ZIP) and the Equity Accelerator Fund, partnering with governments and NGOs to implement tailored, context-specific interventions.
- India's Efforts: India has made significant progress, reducing its share of global zero-dose children and implementing targeted programs
Manufacturing Analytics & Quality Assurance
4:50
The Role of Digital Systems in Enhancing Quality Oversight and Traceability
- Digital Transformation in Pharma. How automation, real-time monitoring, and integrated systems improve quality oversight and traceability.
- Key Technologies & Regulatory Alignment. AI-driven analytics, end‑to‑end digital workflows (ELN/LIMS), connecting experimental data and process control (SIMCA/JMP/MODDE; bioreactor SCADA) with ERP (SAP) for real‑time insights and audit readiness.
- Strategic Benefits & Industry Impact. Enhanced lifecycle traceability. Encryption, backup/restore, and standardized metadata enabling secure, compliant collaboration across R&D and manufacturing sites, improved compliance, and future trends shaping pharmaceutical excellence.
5:15
Chairman’s Closing Remarks
5:20
End of Conference Day 1
6:00
8:50
IMAPAC’s Opening Address
Keynote Address: Navigating Next-Generation Therapies
Digitalization & AI-Driven Transformation
9:25
Fireside Chat: Manufacturing Excellence and Supply Chain Resilience in a Global Environment
- Building resilient and flexible supply chains amid geopolitical, regulatory, and capacity constraints.
- How can companies better align early process development decisions with long-term supply strategies?
- Discussion on manufacturing excellence in the next 5–10 years.
Moderator:
Panelists:
10:15
Morning Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking
Advancements in Cell & Gene Therapy
11:00
11:50
Clinical Advances in Regenerative Medicine
- Current Landscape: Overview of the latest developments and clinical advancements in regenerative medicine.
- Key Challenges: Addressing scientific, regulatory, and translational hurdles in clinical development.
- Transforming Horizons: Innovative strategies to maximize therapeutic potential and accelerate progress.
12:15
Lunch Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking
Regulatory, Scientific, and Commercial Frameworks Shaping Vaccines and Biologics
Happening in Regency Ballroom I
2:25
Recent Developments in Pharmaceutical Regulations & Life Cycle Management
- Addressing the latest regulatory updates and their implications for effective product life cycle management.
- Best practices in sustaining compliance, addressing patient needs, and ensuring competitive positioning within the market.
3:15
Afternoon Tea Break, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking
Closing Panel: Forging India's Vaccine & Biologics Future
4:00
Plenary Discussion: What’s Next for Novel Vaccines & Biologics – Can Innovation, Strategy, and Collaboration Lead the Way?
- Shaping India and the Global South as leaders, not just manufacturers, in vaccines and biologics.
- Harnessing innovation and technology to deliver scalable, accessible solutions for developing nations.
- Building fair, accountable global partnerships that accelerate R&D and impact.
- Aligning policy and regulation to drive speed, quality, and trust.
- Preparing for future health challenges through strategic planning and innovation.
Moderator:
Panelists:
4:50
Chairman’s Closing Remarks
5:00
End of Conference
For Speaking Opportunities, Kindly Contact:
